Hercules Offshore, Inc. (HERO)

Today’s recommendation is entering turnaround territory, with increasing revenues, yet trading at a low valuation. Hercules Offshore, Inc. (HERO) from The Cheap Investor Hercules Offshore, Inc. (HERO) provides shallow-water drilling and marine services to the oil and natural gas exploration and production industry worldwide. Its services oil...
Read More

Curis, Inc. (CRIS)

Today’s pick is a biotech company with important alliances and a pipeline of drugs in clinical tests. Curis, Inc. (CRIS) from The Cheap Investor Curis, Inc. (CRIS) Curis has focused most of its internal resources on developing novel, proprietary small molecule targeted cancer drug candidates. Its principal is...
Read More

Solta Medical (SLTM)

Today’s Daily Alert features a new small-cap recommendation and an update on one of our Top Picks for 2013. Solta Medical (SLTM) from The Cheap Investor Solta Medical is a global leader in the medical aesthetics market providing ... aesthetic energy devices for skin resurfacing and acne...
Read More

Amicus Therapeutics (FOLD)

Today, The Cheap Investor Editor Bill Mathews recommends a low-priced, development-stage pharmaceutical company that is appropriate for speculative investors. Amicus Therapeutics (FOLD) Amicus Therapeutics, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs known as pharmacological chaperones. ... The stock a..
Read More

ArQule, Inc. (ARQL)

Today’s Daily Alert brings a new low-priced pharmaceutical stock idea from The CHEAP Investor. “ArQule, Inc. (ARQL) engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product candidate tivantinib (ARQ 197) is an inhibitor of c-Met...
Read More

Happy Birthday to Us

This year marks the 30th year of the Dick Davis Digests' publication. In addition, later this week, the Investment Digest will publish its 700th issue. Dick Davis started the Digest in 1981, in the middle of a two-year recession. You can see by orange...
Read More